Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
What is Wegovy worth to your employer? Companies wrestle with obesity drugs' costs, long-term value.
09:00am, Wednesday, 10'th Jan 2024
Amid mounting evidence of obesity drugs' longer-term health benefits, thorny questions persist about their value to employers.
Wall Street Doesn't Expect Eli Lilly Stock to Move Much Higher in 2024. Here's Why Analysts Could Be Wrong.
05:51am, Wednesday, 10'th Jan 2024
There's perhaps a surprising lack of enthusiasm on Wall Street about Lilly's near-term prospects. Lilly could soar more than analysts expect with booming sales of Zepbound and a big FDA decision on th
Eli Lilly and Company (LLY) JPMorgan 42nd Annual Healthcare Conference
09:35pm, Tuesday, 09'th Jan 2024
Eli Lilly and Company (LLY) JPMorgan 42nd Annual Healthcare Conference
Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan Seigerman
03:10pm, Tuesday, 09'th Jan 2024
Evan Seigerman, BMO biotech analyst, joins 'Power Lunch' to discuss the rise of pharmaceutical M&A and more.
Eli Lilly CEO David Ricks on GLP-1 and obesity drugs
11:18am, Tuesday, 09'th Jan 2024
David Ricks, Eli Lilly CEO, joins 'Squawk on the Street' to discuss how big the weight loss and obesity drugs will be for the company, the insurance question around their drugs, and more.
3 Simple Tricks That Every Investor Should Use (but Most Don't)
10:15am, Tuesday, 09'th Jan 2024
There's no rule that mandates betting on only one company in a sector. It's valuable to learn about the top people involved in a business.
Where will S&P 500 go after new bullish levels?
08:11am, Tuesday, 09'th Jan 2024
A rally of 1.43% on January 8 brought the broad index back above its 5-day and 10-day lines, as American Airlines Group Inc. NASDAQ: AAL, Arista Networks Inc. NYSE: ANET, Nvidia Corp. NASDAQ: NVDA, Ad
Q1's Rising Stars: 3 Dividend Stocks with Massive Upside
02:28pm, Monday, 08'th Jan 2024
Early in 2023, many investors were seeking out dividend stocks to buy because of expectations for a flat to falling market. But as the risk-on sentiment returns to market, some investors may be turnin
Eli Lilly CEO talks expanding innovation past obesity drugs
02:27pm, Monday, 08'th Jan 2024
Weight-loss drugs became one of the biggest stories in 2023, with Eli Lilly's (LLY) Mounjaro and Zepbound among the pack leaders for GLP-1 pharmaceuticals. Eli Lilly CEO Dave Ricks joins Yahoo Finance
Lilly CEO says weight-loss drug Zepbound weekly prescriptions hit 25,000 in December
02:08pm, Monday, 08'th Jan 2024
Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December, and that its 2024 supply may not be enough to me
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis
03:26pm, Sunday, 07'th Jan 2024
Alphabet unit Isomorphic Labs, which uses AI to help discover new drugs, entered collaboration deals with Eli Lilly and Novartis.
Isomorphic inks deals with Eli Lilly and Novartis for drug discovery
12:51pm, Sunday, 07'th Jan 2024
Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it's entered into strategic partnerships with two pharmaceutical giants, Eli
3 Stocks to Make You the Millionaire Next Door: 2024 Edition
04:21pm, Friday, 05'th Jan 2024
Some growth stocks keep powering ahead. While not immune to market downturns, certain stocks seem to decline less and recover faster than other securities.
Eli Lilly's direct drug sales may not upend the industry alone – but others could follow suit
02:37pm, Friday, 05'th Jan 2024
LillyDirect is the latest attempt to simplify what critics call a complex system for distributing, pricing and prescribing prescription drugs.
NVS or LLY: Which Is the Better Value Stock Right Now?
12:47pm, Friday, 05'th Jan 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity
